Remy is an investment professional on the Frazier Life Sciences team and focuses on identifying unique investment opportunities and working closely with select portfolio companies.
Remy joined Frazier Healthcare Partners in 2015 and focuses on investment identification, due diligence, and deal closing. He also works with select portfolio companies post-investment. He is currently a board observer at Alpine Immune Sciences, Aptinyx, Iterum Therapeutics, and Zavante Therapeutics.
Prior to joining Frazier, Remy was a member of the investment team at GE Ventures and a management consultant in L.E.K. Consulting’s life sciences practice. Remy has also worked with several start-ups, including Maya Medical (acquired by Covidien) and Northstar Neuroscience.
Remy received his Ph.D. in Bioengineering from Stanford University, where he was a National Science Foundation Graduate Research Fellow. Remy’s doctoral research used optogenetics to map neural circuits and to understand the physiologic basis of functional neural imaging, which resulted in publications in Nature and Nature Protocols. He also holds a B.S.E. in Biomedical Engineering from Case Western Reserve University.
Case Western Reserve University (B.S.E.)
Stanford University (Ph.D.)